IM8N Stock Overview
A biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Insmed Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$74.50 |
| 52 Week High | US$78.00 |
| 52 Week Low | US$20.00 |
| Beta | 1.11 |
| 1 Month Change | 7.19% |
| 3 Month Change | 20.16% |
| 1 Year Change | 171.90% |
| 3 Year Change | 268.81% |
| 5 Year Change | 164.18% |
| Change since IPO | 555.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| IM8N | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.2% | -3.2% | 2.7% |
| 1Y | 171.9% | -7.9% | 17.0% |
Return vs Industry: IM8N exceeded the German Biotechs industry which returned -7.9% over the past year.
Return vs Market: IM8N exceeded the German Market which returned 17% over the past year.
Price Volatility
| IM8N volatility | |
|---|---|
| IM8N Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IM8N has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: IM8N's weekly volatility has decreased from 16% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 912 | Will Lewis | www.insmed.com |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.
Insmed Incorporated Fundamentals Summary
| IM8N fundamental statistics | |
|---|---|
| Market cap | €13.52b |
| Earnings (TTM) | -€823.66m |
| Revenue (TTM) | €326.84m |
41.4x
P/S Ratio-16.4x
P/E RatioIs IM8N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IM8N income statement (TTM) | |
|---|---|
| Revenue | US$342.96m |
| Cost of Revenue | US$78.03m |
| Gross Profit | US$264.92m |
| Other Expenses | US$1.13b |
| Earnings | -US$864.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 20, 2025
| Earnings per share (EPS) | -4.83 |
| Gross Margin | 77.25% |
| Net Profit Margin | -252.01% |
| Debt/Equity Ratio | 230.6% |
How did IM8N perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 18:20 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Insmed Incorporated is covered by 32 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neena Bitritto-Garg | Baird |
| Anita Dushyanth | Berenberg |
| Jason Zemansky | BofA Global Research |